Patients with a rare blood disease in which the immune system attacks their own red blood cells now have, for the first time, a treatment approved specifically for their condition.
The Food and Drug Administration approved Imaavy for warm autoimmune hemolytic anemia in adults and children 12 and older who are currently taking or have previously taken corticosteroids. Johnson & Johnson announced the decision on August 24, 2026. The drug, known generically as nipocalimab-aahu, was granted priority review earlier in the year and was already approved for generalized myasthenia gravis.
